Cancer Molecular Pathology of School of Medicine and Dentistry, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.
Pathology Queensland, Gold Coast University Hospital, Southport, QLD, Australia.
Methods Mol Biol. 2022;2534:109-119. doi: 10.1007/978-1-0716-2505-7_8.
American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (AJCC/UICC) staging and American Thyroid Association (ATA) risk predication system are the best predicators of mortality and cancer recurrence, respectively, in patients with differentiated thyroid carcinoma, including papillary thyroid carcinoma. In ATA risk stratification of differentiated thyroid carcinomas, clinical features, nodal features, and pathological features are assessed. Many of the features are also assessed in pathological staging. The prognostic stage grouping of papillary thyroid carcinoma in AJCC/UICC depends on the age of the patients as well as the standard parameters-extent of tumor (T), lymph node status (N), and presence of distant metastasis (M). Major changes noted in the current pathological staging protocol include the cut-off age from 45-year to 55-year in grouping of patients, use of gross invasion of strap muscles instead of minimal microscopic extrathyroidal extensions as T3b and downstage of many prognostic groups such as those with lymph node metastases (without distant metastases) from Stage III to Stage II. The staging protocol have moved many patients with papillary thyroid carcinoma into good prognostic groups for better predication of patients' survival rates and to avoid unnecessary treatment. This new approach has been verified by different groups globally, although modifications could be expected in the future for better prognostic assessment in patients with papillary thyroid carcinoma.
美国癌症联合委员会/国际癌症控制联盟(AJCC/UICC)分期和美国甲状腺协会(ATA)风险预测系统分别是预测分化型甲状腺癌(包括甲状腺乳头状癌)患者死亡率和癌症复发率的最佳指标。在 ATA 对分化型甲状腺癌的风险分层中,评估了临床特征、淋巴结特征和病理特征。许多特征也在病理分期中进行评估。AJCC/UICC 中甲状腺乳头状癌的预后分期分组取决于患者的年龄以及标准参数——肿瘤的范围(T)、淋巴结状态(N)和远处转移(M)。当前病理分期方案中注意到的主要变化包括将患者分组的截止年龄从 45 岁提高到 55 岁,使用颈阔肌的大体侵犯代替微小的甲状腺外延伸作为 T3b,以及将许多预后组(如无远处转移的淋巴结转移)从 III 期降级为 II 期。该分期方案将许多甲状腺乳头状癌患者转移到预后较好的组中,以更好地预测患者的生存率,并避免不必要的治疗。这一新方法已被全球不同的研究组验证,尽管未来可能会对甲状腺乳头状癌患者的预后评估进行修改,以达到更好的效果。